An original multiplex method to assess five different SARS-CoV-2 antibodies.
COVID-19
SARS-CoV-2
kinetics
multiplex
serology
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
27 04 2021
27 04 2021
Historique:
received:
04
11
2020
accepted:
01
12
2020
pubmed:
9
2
2021
medline:
30
4
2021
entrez:
8
2
2021
Statut:
epublish
Résumé
Accurate SARS-CoV-2 serological assays are urgently needed to help diagnose infection, determine past exposure of populations and assess the response to future vaccines. The study aims at assessing the performance of the multiplex D-tek COVIDOT 5 IgG assay for the detection of SARS-CoV-2 IgG antibodies (N, S1+S2, S1, S2 and RBD). Sensitivity and dynamic trend to seropositivity were evaluated in 218 samples obtained from 46 rRT-PCR confirmed COVID-19 patients. Non-SARS-CoV-2 sera (n=118) collected before the COVID-19 pandemic with a potential cross-reaction to the SARS-CoV-2 immunoassay were included in the specificity analysis. A gradual dynamic trend since symptom onset was observed for all IgG antibodies. Sensitivities before day 14 were suboptimal. At ≥21 days, sensitivities reached 100% (93.4-100%) for N, S1+S2, S2 and RBD-directed IgG and 96.3% (87.3-99.6%) for S1-directed IgG. In 42 out of 46 patients (91.3%), all five antibodies were detected at ≥14 days. The four remaining patients had between 2 and 4 positive antibodies at their respective maximal follow-up period. The specificity was 100 % for S1+S2, S2 and RBD, 98.3% for N and 92.4% (86.0-96.5%) for S1-directed IgG. The combined use of antigens increases the early sensitivity whilst enforcing high specificity. Sensitivities at ≥21 days and specificities were excellent, especially for N, S1+S2, S2 and RBD-directed IgG. Caution is however required when interpreting single S1-directed reactivities. Using a multiplex assay complies with the orthogonal testing algorithm of the CDC and allows a better and critical interpretation of the serological status of a patient.
Identifiants
pubmed: 33554567
doi: 10.1515/cclm-2020-1652
pii: cclm-2020-1652
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
971-978Informations de copyright
© 2020 Walter de Gruyter GmbH, Berlin/Boston.
Références
World Health Organization. Coronavirus disease 2019 (COVID-19) situation report – weekly evaluation update 17 November 2020.
Vashist, SK. In vitro diagnostic assays for COVID-19: recent advances and emerging trends. Diagnostics 2020;10:202. https://doi.org/10.3390/diagnostics10040202.
Farnsworth, CW, Anderson, NW. SARS-CoV-2 serology: much hype, little data. Clin Chem 2020;66:875–7. https://doi.org/10.1093/clinchem/hvaa107.
Zhao, J, Yuan, Q, Wang, H, Liu, W, Liao, X, Su, Y, et al.. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020;71:2027–34. https://doi.org/10.1093/cid/ciaa344.
Jaaskelainen, AJ, Kuivanen, S, Kekalainen, E, Ahava, MJ, Loginov, R, Kallio-Kokko, H, et al.. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol 2020;129:104512. https://doi.org/10.1016/j.jcv.2020.104512.
Van Elslande, J, Decru, B, Jonckheere, S, Van Wijngaerden, E, Houben, E, Vandecandelaere, P, et al.. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect 2020;26:1557.e1–7. https://doi.org/10.1016/s1473-3099(20)30846-x.
Theel, ES, Harring, J, Hilgart, H, Granger, D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol 2020;58:e01243–20. https://doi.org/10.1128/JCM.01243-20.
Premkumar, L, Segovia-Chumbez, B, Jadi, R, Martinez, DR, Raut, R, Markmann, A, et al.. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020;5:eabc8413. https://doi.org/10.1126/sciimmunol.abc8413.
McAndrews, KM, Dowlatshahi, DP, Dai, J, Becker, LM, Hensel, J, Snowden, LM, et al.. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight 2020;5:e142386. https://doi.org/10.1172/jci.insight.142386.
Liu, W, Liu, L, Kou, G, Zheng, Y, Ding, Y, Ni, W, et al.. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol 2020;58:e00461–20. https://doi.org/10.1128/JCM.00461-20.
Walls, AC, Park, YJ, Tortorici, MA, Wall, A, McGuire, AT, Veesler, D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281–92.e6. https://doi.org/10.1016/j.cell.2020.02.058.
Lan, J, Ge, J, Yu, J, Shan, S, Zhou, H, Fan, S, et al.. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215–20. https://doi.org/10.1038/s41586-020-2180-5.
GeurtsvanKessel, CH, Okba, NMA, Igloi, Z, Bogers, S, Embregts, CWE, Laksono, BM, et al.. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 2020;11:3436. https://doi.org/10.1038/s41467-020-17317-y.
Horber, S, Soldo, J, Relker, L, Jurgens, S, Guther, J, Peter, S, et al.. Evaluation of three fully-automated SARS-CoV-2 antibody assays. Clin Chem Lab Med 2020;58:2113–20. https://doi.org/10.1515/cclm-2020-0975.
Winter, AK, Hegde, ST. The important role of serology for COVID-19 control. Lancet Infect Dis 2020;7:758–9. https://doi.org/10.1016/S1473-3099(20)30322-4.
Tre-Hardy, M, Wilmet, A, Beukinga, I, Favresse, J, Dogne, JM, Douxfils, J, et al.. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. J Med Virol 2020;15. https://doi.org/10.1002/jmv.26303.
Lippi, G, Plebani, M. SARS-CoV-2 antibodies titration: a reappraisal. Ann Transl Med 2020;8:1032. https://doi.org/10.21037/atm-20-5361.
Tré-Hardy, M, Blairon, L, Wilmet, A, Beukinga, I, Malonne, H, Dogné, J-M. The role of serology for COVID-19 control: population, kinetics and test performance do matter. J Infect 2020;81:e91–2. https://doi.org/10.1016/j.jinf.2020.05.019.
Hachim, A, Kavian, N, Cohen, CA, Chin, AWH, Chu, DKW, Mok, CKP, et al.. ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat Immunol 2020;21:1293–301. https://doi.org/10.1038/s41590-020-0773-7.
D-tek. Instruction for use — BlueDiver COVIDOT 5 IgG — BlueDiver protocol: 02; 2020.
Scohy, A, Anantharajah, A, Bodeus, M, Kabamba-Mukadi, B, Verroken, A, Rodriguez-Villalobos, H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol 2020;129:104455. https://doi.org/10.1016/j.jcv.2020.104455.
Long, QX, Liu, BZ, Deng, HJ, Wu, GC, Deng, K, Chen, YK, et al.. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845–8. https://doi.org/10.1038/s41591-020-0897-1.
Favresse, J, Eucher, C, Elsen, M, Tre-Hardy, M, Dogne, JM, Douxfils, J. Clinical performance of the elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin Chem 2020;66:1104–6. https://doi.org/10.1093/clinchem/hvaa131.
Plebani, M, Padoan, A, Negrini, D, Carpinteri, B, Sciacovelli, L. Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? Clin Chim Acta 2020;509:1–7. https://doi.org/10.1016/j.cca.2020.05.050.
den Hartog, G, Schepp, RM, Kuijer, M, GeurtsvanKessel, C, van Beek, J, Rots, N, et al.. SARS-CoV-2-Specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis 2020;222:1452–61. https://doi.org/10.1093/infdis/jiaa479.
Padoan, A, Cosma, C, Sciacovelli, L, Faggian, D, Plebani, M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med 2020;58:1081–8. https://doi.org/10.1515/cclm-2020-0443.
Bohn, MK, Lippi, G, Horvath, A, Sethi, S, Koch, D, Ferrari, M, et al.. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med 2020;58:1037–52. https://doi.org/10.1515/cclm-2020-0722.
Pfluger, LS, Bannasch, JH, Brehm, TT, Pfefferle, S, Hoffmann, A, Norz, D, et al.. Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. J Clin Virol 2020;130:104549. https://doi.org/10.1016/j.jcv.2020.104549.
Favresse, J, Eucher, C, Elsen, M, Laffineur, K, Dogne, JM, Douxfils, J. Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study. Clin Chem Lab Med 2020;58:e193–6. https://doi.org/10.1515/cclm-2020-0962.
Tre-Hardy, M, Wilmet, A, Beukinga, I, Dogne, JM, Douxfils, J, Blairon, L. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin Chem Lab Med 2020;58:1357–64.
Van Elslande, J, Houben, E, Depypere, M, Brackenier, A, Desmet, S, Andre, E, et al.. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect 2020;26:1082–7. https://doi.org/10.1016/j.cmi.2020.05.023.
Liu, ZL, Liu, Y, Wan, LG, Xiang, TX, Le, AP, Liu, P, et al.. Antibody profiles in mild and severe cases of COVID-19. Clin Chem 2020;66:1102–4. https://doi.org/10.1093/clinchem/hvaa137.
Mairesse, A, Favresse, J, Eucher, C, Elsen, M, Tre-Hardy, M, Haventith, C, et al.. High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. Clin Biochem 2020;86:23–7. https://doi.org/10.1016/j.clinbiochem.2020.08.009.
Fill Malfertheiner, S, Brandstetter, S, Roth, S, Harner, S, Buntrock-Dopke, H, Toncheva, AA, et al.. Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: a prospective longitudinal study. J Clin Virol 2020;130:104575. https://doi.org/10.1016/j.jcv.2020.104575.
Ayouba, A, Thaurignac, G, Morquin, D, Tuaillon, E, Raulino, R, Nkuba, A, et al.. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol 2020;129:104521. https://doi.org/10.1016/j.jcv.2020.104521.
Johnson, M, Wagstaffe, HR, Gilmour, KC, Mai, AL, Lewis, J, Hunt, A, et al.. Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. J Clin Virol 2020;130:104572. https://doi.org/10.1016/j.jcv.2020.104572.
van Tol, S, Mogling, R, Li, W, Godeke, GJ, Swart, A, Bergmans, B, et al.. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. Emerg Microb Infect 2020;9:1965–73. https://doi.org/10.1080/22221751.2020.1813636.
Gillot, C, Douxfils, J, Cadrobbi, J, Laffineur, K, Dogné, J-M, Elsen, M. An original ELISA-based multiplex method for the simultaneous detection of 5 SARS-CoV-2 IgG antibodies directed against different antigens. J Clin Med 2020;9:3752. https://doi.org/10.3390/jcm9113752.
Interim guidelines for covid-antibody testing. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html [Accessed 1 Aug 2020].
Havers, FP, Reed, C, Lim, T, Montgomery, JM, Klena, JD, Hall, AJ, et al.. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020. JAMA Intern Med 2020. https://doi.org/10.1001/jamainternmed.2020.4130.
Fischer, B, Knabbe, C, Vollmer, T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Euro Surveill 2020;25:2001285. https://doi.org/10.2807/1560-7917.es.2020.25.28.2001285.
Stringhini, S, Wisniak, A, Piumatti, G, Azman, AS, Lauer, SA, Baysson, H, et al.. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 2020;396:313–9. https://doi.org/10.1016/s0140-6736(20)31304-0.
Soleimani, R, Khourssaji, M, Gruson, D, Rodriguez-Villalobos, H, Berghmans, M, Belkhir, L, et al.. Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients. J Med Virol 2020. https://doi.org/10.1002/jmv.26430.
Lee, N, McGeer, A. The starting line for COVID-19 vaccine development. Lancet 2020;395:1815–6. https://doi.org/10.1016/s0140-6736(20)31239-3.
Levinson, SS. SARS-CoV-2 serology - need for quantitative testing and interpretive reporting. J Appl Lab Med 2020;1420–2. https://doi.org/10.1093/jalm/jfaa147.
Atyeo, C, Fischinger, S, Zohar, T, Slein, MD, Burke, J, Loos, C, et al.. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity 2020;53:524–32.e4. https://doi.org/10.1016/j.immuni.2020.07.020.